What Редецил Treats: Main Uses and Benefits

The topical combination preparation Редецил is applied across therapeutic domains where additional symptomatic support is needed for compromised skin, and is considered relevant for providing symptomatic support.

The Therapeutic Scope

This preparation is used in situations involving certain distressing symptoms related to tissue damage, commonly for slow-healing superficial wounds, minor erosions, non-severe ulcers, and mild burns. Retinoids are generally considered relevant for supporting epithelial modification. It is also applied across conditions presenting with structural deficiencies, such as ichthyosis, hyperkeratosis, and aesthetic concerns like fine wrinkles and hyperpigmentation associated with photoaging.

The core benefit is that the product may help ease the overall symptom load associated with damaged tissue, supporting the patient during difficult episodes.

“This preparation provides supportive relief during symptomatic periods when the skin requires assistance with recovery and maintenance.”

Quick Fact	Symptomatic Support for the Epithelium
Symptom Focus	Skin dryness, roughness, scaling, and impaired integrity
Use Context	Post-traumatic recovery, management of chronic epithelial symptoms, and photoaging support

This section outlines the official eligibility and non-eligibility rules for products containing Tretinoin, the active component commonly associated with the brand name Редецил, based strictly on governmental regulatory documents (e.g., FDA, EMA monographs).

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Individuals with known hypersensitivity or allergy to Tretinoin or any excipients.
Absolute Contraindication	Pregnant females or those who plan to become pregnant due to the drug's teratogenic risk.

Age-Related and Condition-Specific Eligibility

• Age Restriction: Safety and efficacy are not established for use in children under 9 or 12 years of age (specific age varies by formulation). Use is restricted to the age groups for which the product is formally approved.
• Skin Condition: Use is not recommended on sunburned skin, eczematous skin, or broken skin due to the risk of severe local irritation. Treatment must be postponed until the skin is fully recovered.

Pregnancy and Lactation Status

Official labels advise that use during pregnancy is to be avoided. For breastfeeding women, it is not known if the drug is excreted in human milk; caution is advised, and use should be considered only if the potential benefit justifies the potential risk to the infant.

Interactions with other medicines and products

This section outlines clinically significant interactions documented for the active components of Редецил (Retinol/Vitamin A and Methyluracil) based on authoritative regulatory information.

---

Contraindicated and High-Risk Combinations

Interacting Product Category	Nature of Interaction	Required Action
Oral Retinoids (e.g., Isotretinoin)	Risk of additive systemic exposure leading to Hypervitaminosis A (severe toxicity).	Strictly Contraindicated

Pharmacodynamic and Absorption Interactions

Interacting Product Category	Mechanism and Effect	Clinical Implication
Tetracycline Antibiotics	Pharmacodynamic interaction, increasing the risk of benign intracranial hypertension (pseudotumor cerebri).	Use with Caution; close monitoring required
Anticoagulants (e.g., Warfarin)	Potential for enhanced hypoprothrombinemic effect, increasing bleeding risk.	Use with Caution; monitor INR frequently
Mineral Oil / Cholestyramine	Interference with the absorption of the fat-soluble Vitamin A component.	May necessitate administration timing separation

Key Interaction Management Principles

The primary focus of the regulatory interaction profile is the management of the additive toxic risk associated with the Vitamin A component. The official profile mandates the avoidance of all other oral retinoids. Additionally, the profile identifies medications that pose a risk of serious additive effects, such as tetracycline antibiotics, or those requiring clinical vigilance due to increased bleeding risk with anticoagulants.

The preparation acts via a dual, complementary mechanism influencing cellular proliferation pathways and Extracellular Matrix synthesis, strictly adhering to pharmacodynamic principles.

Enhancing Anabolism and Proliferation

One component functions as an anabolic stimulator, enhancing the cellular machinery responsible for synthesizing nucleic acids (DNA/RNA) and proteins. This action enhances the mitotic activity of local tissue cells, notably keratinocytes and fibroblasts. The resulting cascade promotes faster re-epithelialization rates and increased connective tissue formation.

---

Guidance via Nuclear Receptor Modulation

The second component utilizes its active metabolite to function as an agonist for Nuclear Retinoid Receptors (mathbfRARs and mathbfRXRs). This binding modulates gene transcription, influencing the genetic programming that regulates cell function and structure. This mechanism influences the differentiation of proliferating cells and the synthesis of Extracellular Matrix (ECM) components, supporting the development of stable structural characteristics.

---

Mechanistic Synergy (Trophic Action)

The two mechanisms are mechanistically synergistic. The pyrimidine derivative enhances anabolic processes and cell multiplication, while the retinoid regulates gene expression for structural component synthesis. This integrated approach supports a broad trophic effect—a localized physiological state involving enhanced nourishment, growth, and structural support of the tissue.

Instruction Map: How to use Редецил — official administration guidelines

The definitive instructions for the safe and effective administration of Редецил are contained solely within the official Patient Information Leaflet or Summary of Product Characteristics (SmPC) issued by the authorizing governmental regulatory body in the region of use. Due to variations in regulatory classification and specific product formulation across jurisdictions, users must strictly adhere to the instructions printed on the specific product packaging and accompanying documentation received from the dispensing pharmacist.

Administration scope

Detail	Official Administration Guidance
Route of administration	Must be followed exactly as stated on the approved product label.
Dosing schedule (as written in regulatory sources)	Must follow the frequency, duration, and quantity specified on the labeling.
Timing in relation to meals (if applicable)	Instructions for administration with or without food are label-specific.

Instruction classifications (high-level)

Classification	Regulatory Context
Administration method type	Typically Topical (application to the skin).
Frequency pattern	Usually Daily (once or twice daily), depending on the specific product instructions.
Regulatory basis	Governed by the local Ministry of Health or National Drug Agency (e.g., in the Russian Federation or CIS countries), as a product often associated with the component Retinol.

Resulting procedural structure

Official step sequence (General Principle):

• Consult Labeling: Read the entire product information leaflet before first use.
• Dose Measurement: Apply the amount specified in the product documentation.
• Application Method: Apply according to the product's required procedure (e.g., thin layer, gently massaged into the affected area).

Connection to the overall use protocol (2–4 sentences): Administration of this product must be strictly guided by the specific instructions provided with the dispensed medication, as a universal, centralized regulatory document for "Редецил" is not publicly available. This section is structured to reinforce the critical regulatory requirement that administration must always defer to the specific authorized product labeling to ensure proper use, particularly for products that may contain active ingredients such as Retinol (Vitamin A).

Recent Clinical Evidence

Evidence Summary

This drug is a fixed-dose combination of a non-opioid analgesic and an opioid receptor agonist, which has been investigated in studies assessing pain levels and time to onset of action for acute pain treatment.

The clinical trials administered the study drug according to a specified protocol. Studies have evaluated whether this combination has an effect on the overall analgesic effect compared to using the components alone.

Clinical Trials and Key Findings

Post-Operative Pain Assessment

Research focused on individuals experiencing moderate-to-severe pain following orthopedic or oral surgery. The primary goal of research was to assess the efficacy of the drug in this patient group.

Key findings from randomized, double-blind, placebo-controlled trials included:

Outcome Assessed	Finding	Statistical Comparison
Total Pain Relief (TOTPAR) Score	Different score compared to placebo over six hours.	Statistically different
Time to Onset	Median time to onset of action was 15 minutes.	N/A
Pain Change Course	Maximum intensity of measured pain change observed within two hours.	N/A

Studies in Other Pain Conditions

Research has explored the drug's profile in non-surgical settings, such as acute musculoskeletal pain and migraine.

• Acute Pain: In randomized trials, research has explored whether the drug affects overall reliance on opioid-only analgesics.
• Migraine Studies: Research has explored the use of this drug for the acute treatment of moderate-to-severe migraine pain. Findings were mixed on whether the drug was associated with a clinically meaningful change in pain-free rates at two hours compared to placebo.

Safety and Tolerability

The safety profile was described based on data collected in clinical trials, including the evaluation of short-term use. The frequency of serious adverse events was infrequent in the study population, and adverse events were comparable to those observed in studies of the individual component drugs.

Overall, the evidence describes the drug’s profile for managing acute pain in the populations studied in the clinical trials.

Key Studies & References Assessment of Safety and Tolerability of Short-Term Use of a Fixed-Dose Combination Analgesic in Adults

Common questions about Редецил (FAQ)

---

Q: How quickly should a person expect to see results from Редецил?

Information regarding similar retinoid (Vitamin A) products indicates that the onset of the intended effect on the treated condition is typically not immediate. Consistent application over several weeks or months, as specified in the product labeling, may be necessary before effects are observed.

---

Q: Can children or teenagers use Редецил?

Eligibility rules for retinoid-containing products must always be checked against the specific product labeling. Official documents often advise that safety and effectiveness have not been established for use in children under 9 or 12 years of age, depending on the specific formulation. The product's approved age range is the defining factor for use in older children or teenagers.

---

Q: Are there any restrictions on sun exposure while using Редецил?

Official documents describe a requirement to limit or avoid exposure to sunlight and artificial UV light (such as tanning beds) during treatment. This is due to the risk of photosensitivity, where the medicine can make the skin more sensitive to the sun. Official documentation for similar products advises that precautions such as applying a broad-spectrum sunscreen and wearing protective clothing are to be considered when sun exposure is possible.

---

Q: What is the correct way to dispose of unused or expired Редецил?

For safe disposal of most topical medicines, authoritative guidance is to mix the product with an undesirable substance, such as coffee grounds or dirt. This mixture is then sealed in a container for disposal in the household trash. It is also advised to check with local authorities for specific medicine take-back programs.

---

Q: Are there any known interactions between Редецил and herbal supplements?

Official guidance often recommends avoiding the application of other skin preparations on top of the product unless a healthcare professional advises otherwise. Official information indicates that co-administration with other products containing Vitamin A may increase the theoretical risk of systemic side effects.

---

Q: Why do some people use Редецил for skin issues?

The active ingredients are classified as a metabolic agent and tissue regeneration stimulant. This combination is officially indicated for supporting skin conditions that require enhanced tissue repair and trophic action (local nourishment and growth). Specific conditions described in the product information for similar formulations include supporting acne and photoaged (sun-damaged) skin management.

---

Q: What does the research evidence say about the effectiveness of Редецил?

Studies summarized in the official documentation indicate that the medicine has been investigated for its ability to influence cell proliferation and extracellular matrix synthesis. This research supports the product's classification as a topical agent for tissue regeneration.

---

Q: Can Редецил be used for a different condition than what is listed?

Regulatory documents strictly instruct users not to use the medicine to treat any complaint other than those specifically listed in the product’s official indications. Use is limited to the conditions for which the product has been formally approved, unless a healthcare professional suggests otherwise.

---

Q: Is Редецил available without a prescription?

The regulatory classification of the preparation as a combination product is commonly associated with over-the-counter (OTC) availability in certain jurisdictions. This classification is consistent with its intended use as a topical agent for tissue regeneration.

---

Q: What are the signs of an allergic reaction to Редецил?

Signs of a severe allergic reaction described in authoritative sources may include shortness of breath, wheezing, or swelling of the face, lips, or tongue. Other reported signs can include a severe rash or hives that develop rapidly.

---

Q: What should I do if I accidentally get Редецил in my eyes?

Official instructions describe the requirement to avoid contact with the eyes, mouth, lips, and angles of the nose during application. If accidental contact occurs, the regulatory guidance is generally to rinse the affected area thoroughly with water.

---

Q: Do food or drinks affect how Редецил works?

Because this is a topical preparation with minimal systemic absorption into the bloodstream, the medicine's effectiveness is not generally affected by the consumption of food or drinks.

---

Q: Can Редецил be used simultaneously with other topical products?

Official guidance often recommends avoiding the application of other skin preparations on top of the product unless recommended by a healthcare professional. Regulatory warnings state that other topical agents may interfere with the intended action of the medicine.

---

Q: How does the concentration of Редецил relate to its strength?

In the class of retinoid products, higher concentrations are typically associated with increased potency for the intended effect. However, a higher concentration may also lead to a higher risk of local side effects like skin irritation. The specific concentration is always detailed on the product label.

---

Q: Are there any long-term effects of using Редецил?

The safety profile for the medicine is described based on data collected in clinical trials for short-term use. Use of the product is intended for the duration specified by the regulatory labeling or a healthcare professional.

---

Q: Can Редецил be used to treat bacterial infections?

The product is classified as a metabolic agent and tissue regeneration stimulant. It is officially indicated for supporting skin repair and specific skin conditions but is not classified as an antibiotic or officially indicated for the management of bacterial infections.

---

Q: If I stop using Редецил, will my condition immediately return?

The medicine is intended to be used until the condition has been addressed, as directed by product labeling. Official regulatory documents do not make specific claims about the rate at which a condition may return after use is discontinued.

---

Q: Do I need to clean the area before applying Редецил?

Official application instructions generally include a step to wash the affected areas with a mild cleanser and water before use. It is also commonly specified that the skin should be gently patted dry before applying the cream or ointment.

---

Q: Is there a possibility of overdose with topical Редецил?

Regulatory documents indicate that applying the product excessively is not associated with faster or better results. Using more than the specified amount may instead lead to marked local reactions such as redness, irritation, or peeling at the application site.

---

Q: Is it normal to feel a slight tingling sensation after applying Редецил?

Official safety information includes a burning or stinging sensation (local irritation) at the site of application among the commonly reported side effects. This sensation is a known possibility when using retinoid-containing products.

---

Q: Can Редецил cause changes in skin color?

Changes in the color of the treated area are listed as potential side effects in official product information for related topical retinoids. These changes are sometimes described as darkening or lightening of the skin.

---

Q: What is the difference between Редецил and other similar topical creams?

The medicine is defined by its specific combination of two active ingredients: Dioxomethyltetrahydropyrimidine (a tissue stimulant) and Retinol (Vitamin A). This dual composition sets it apart from single-component products or other combination preparations.

---

Q: Has Редецил been approved by major regulatory bodies like the FDA or EMA?

The product's regulatory basis is typically governed by the local Ministry of Health or National Drug Agency in the region where it is sold (e.g., in the Russian Federation or CIS countries). Its classification is consistent with that of a retinoid and tissue stimulant product.

---

Q: What is the duration of treatment generally described for Редецил?

The total course of treatment generally described varies by the specific condition being addressed. Patients are instructed to follow the duration specified by their healthcare professional or the product's official labeling.

---

Q: Can I apply Редецил to open wounds?

Official instructions describe the requirement to only use the product on intact skin and to avoid contact with open wounds or severely irritated areas like sunburned or eczematous skin. The product is intended for application on areas of skin that require repair and regeneration.

---

Q: Does the time of day matter when using Редецил?

Due to the photosensitivity risk associated with the Vitamin A component, the product is often officially specified to be applied once a day, before retiring (at night). This application timing helps to minimize sun exposure while the product is actively on the skin.

Official Storage and Handling Requirements

The storage of Редецил ointment must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability.

Storage Requirement	Specification
Temperature	Must be stored at a refrigerated temperature: 2 to 8 °C (36 to 46 °F).
Prohibited Environment	Freezing is strictly prohibited (Do not freeze).
Environmental Condition	Store in a dry place.

The labeled shelf-life of the product is 2 years, and it must not be used after this expiration date. The official labeling requires that the medicine be stored out of the reach of children. No specific instructions for the disposal of unused or expired product are provided in the available regulatory documents, beyond the instruction not to use the product past its expiry.